MedPath

Carbamazepine

Generic Name
Carbamazepine
Brand Names
Carbatrol, Carnexiv, Epitol, Equetro, Tegretol
Drug Type
Small Molecule
Chemical Formula
C15H12N2O
CAS Number
298-46-4
Unique Ingredient Identifier
33CM23913M
Background

Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.

Indication

Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia. In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures. Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder. Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.

Associated Conditions
Acute Mania, Alcohol Withdrawal Syndrome, Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Mixed manic depressive episode, Pain, Partial Seizures With Secondary Generalization, Restless Legs Syndrome (RLS)

Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment

Phase 2
Completed
Conditions
Spasms, Infantile
Epilepsy
First Posted Date
2000-02-25
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
30
Registration Number
NCT00004758

Drug Therapy for Alcohol Detoxification

Phase 4
Completed
Conditions
Alcoholism
First Posted Date
1999-11-03
Last Posted Date
2005-06-24
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Registration Number
NCT00000441
Locations
🇺🇸

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, United States

Pharmacotherapy and Intensive Treatment - 2

Phase 4
Completed
Conditions
Cocaine-Related Disorders
Substance-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
353
Registration Number
NCT00000218
Locations
🇺🇸

University of Kansas, Kansas City, Missouri, United States

Carbamazepine Treatment of Cocaine Dependence - 1

Phase 2
Completed
Conditions
Substance-Related Disorders
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-04-07
Lead Sponsor
Medical University of South Carolina
Registration Number
NCT00000242
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Carbamazepine Treatment for Cocaine Dependence - 5

Phase 2
Completed
Conditions
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2015-05-28
Lead Sponsor
University of Pennsylvania
Registration Number
NCT00000191
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

Phase 2
Completed
Conditions
Substance-Related Disorders
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2015-04-16
Lead Sponsor
University of Kansas
Registration Number
NCT00000217
Locations
🇺🇸

University of Kansas, Kansas City, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath